Shares Investor Evening (London)


Allergy Therapeutics (AGY)

We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.


BMR has successfully developed a proprietary acid/brine leach process that enables it to achieve high metal recoveries from the different tailings deposits.

BMR Group PLC is listed on AIM under the ticker BMR.

The Company is focused on the recovery of lead and zinc from the tailings deposits of Zambia’s oldest mine at Kabwe.

Central Asia Metals (CAML)

Central Asia Metals (CAML) is an AIM-listed UK company based in London and owns 100% of the Kounrad SX-EW copper project in Kazakhstan. The company has been producing copper at industry leading cash costs for five years and will continue beyond 2030. CAML has a dividend policy of distributing to shareholders a minimum of 20% of gross revenue from Kounrad and has to date returned over $95m to its investors. The Company also has an effective 80% interest in the Shuak copper property in northern Kazakhstan and will begin a detailed exploration programme in Q2 2017.

MaxCyte (MXCT)

MaxCyte is a leader in cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is focused in applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of chronic and acute diseases. MaxCyte's customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicine and active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs.

Palace Capital (PCA)

Palace Capital is a UK property investment company listed on the Alternative Investment Market (AIM) of The London Stock Exchange. The company is not sector specific and looks for opportunities where we can enhance the long-term income and capital value through asset management and strategic capital development.